Last quarter (Q4 2023), Compass Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Compass Therapeutics's net income was $-32.84M. See Compass Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 50.36M	$ 50.36M	$ -41.66M	$ -81.88M	$ 27.81M	$ 34.05M
Operating Income	$ -50.36M	$ -50.36M	$ -41.66M	$ -81.88M	$ -27.81M	$ -34.05M
Net Non Operating Interest Income Expense	$ 7.87M	$ 7.87M	$ 2.36M	$ 399.00K	$ -820.00K	$ -485.00K
Other Income Expense	$ -7.87M	$ -7.87M	$ -2.43M	$ 299.00K	$ -836.00K	$ -116.00K
Pretax Income	$ -42.49M	$ -42.49M	$ -39.23M	$ -82.18M	$ -29.47M	$ -34.65M
Tax Provision	-	-	-	-	$ 32.00K	$ 91.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -42.49M	$ -42.49M	$ -39.23M	$ -82.18M	$ -29.50M	$ -34.74M
Basic EPS	$ -0.34	$ -0.33	$ -0.37	$ -1.31	$ -0.57	$ -0.67
Diluted EPS	$ -0.34	$ -0.33	-	$ -1.31	$ -0.57	$ -0.67
Basic Average Shares	$ 508.11M	$ 127.03M	$ 105.19M	$ 62.87M	$ 52.11M	$ 52.11M
Diluted Average Shares	$ 508.11M	$ 127.03M	-	-	$ 52.11M	$ 52.11M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 50.36M	$ 50.36M	$ -41.66M	$ -81.88M	$ 27.81M	$ 34.05M
Net Income From Continuing And Discontinued Operation	$ -42.49M	$ -42.49M	$ -39.23M	$ -82.18M	$ -29.50M	$ -34.74M
Normalized Income	$ -18.47M	$ -33.57M	-	-	$ -28.89M	$ -34.66M
Interest Expense	-	-	-	-	$ 908.00K	$ 1.23M
EBIT	$ -44.39M	$ -42.49M	$ -41.59M	$ -82.58M	$ -28.56M	$ -33.42M
EBITDA	$ -35.10M	$ -43.83M	$ -40.48M	$ -80.96M	$ -26.16M	$ -31.30M

Currency in USD

Compass Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing